Shifting paradigms in uterine fibroids treatment: insights from current therapeutic approaches

Authors

  • Aranza Vázquez Ruvalcaba Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México
  • Aurora Guadalupe García García Clínica Del Pilar, Guadalajara, Jalisco, México
  • Morelia Yunuen López Cornejo Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México
  • Avhril Alejandra Morales Palacios Universidad Autónoma de Guadalajara, Guadalajara, Jalisco, México
  • Fernando Hernández Vespero Escuela Superior de Medicina Del Instituto Politécnico Nacional, Ciudad de México, México

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20232317

Keywords:

Ulipristal acetate, Leuprolide acetate, Uterine fibroids, Diagnosis, Side effects, Quality of life, Patient satisfaction, Efficacy

Abstract

This review examined the effectiveness of ulipristal acetate (UPA) compared to leuprolide acetate (LEU) in the treatment of symptomatic uterine fibroids. The primary objective was to analyze relevant studies that investigated the improvement of symptoms, complications, alternative treatment options, and surgical outcomes for fibroids. Using the PICO format as a research approach, various aspects were compared for each treatment, including diagnostic accuracy, side effects, quality of life, and patient satisfaction measured through the Uterine fibroid symptoms and quality of life scale. UPA proved to be a safe, well-tolerated, and effective treatment option for symptomatic uterine fibroids, leading to amenorrhea and reduced heavy menstrual bleeding. On the other hand, LEU also effectively reduced fibroid size but had a higher incidence of adverse events such as hot flashes, vaginal dryness, and decreased bone density. It is crucial to consider all the aforementioned factors when selecting the most suitable treatment option for individual patients, as each treatment has its own advantages and disadvantages, including dosing requirements, side effects, endometrial changes, and their impact on treatment adherence and outcomes. Currently, there is limited evidence supporting the superiority of UPA over other drugs like LEU in short-term therapy for symptomatic uterine fibroids. Further research is necessary to establish UPA as a reliable and promising alternative. Treatment decisions should be individualized, taking into account patient comorbidities and considering both surgical and conservative approaches.

References

Águas F, Guerreiro F, Ponte C, Gomes C, Martinho M, Vilhena V, et al. Management of symptomatic uterine fibroids with ulipristal acetate: A retrospective, multicentric and nationwide study. J Gynecol Obstet Hum Reprod. 2020;49(8):101862.

Biscione A, Barra V, Bellone E, Severi FM, Luisi S. Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis. Gynecol Endocrinol. 2020;36(1):87-92.

Brun JL, Rajaonarison J, Froeliger A, Monseau-Thiburce AC, Randriamboavonjy R, Vogler A. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy. Eur J Obstet Gynecol Reprod Biol. 2018;222:13-8.

Mamane B, Havelock J, Hemmings R, Reproductive endocrinology and infertility committee; special contributor. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can. 2015;37(3):277-85.

Combs A, Singh B, Nylander E, Islam MS, Nguyen HV, Parra E, et al. A Systematic Review of Vitamin D and Fibroids: Pathophysiology, Prevention, and Treatment. Reprod Sci. 2023;30(4):1049-64.

Coutinho LM, Assis WA, Spagnuolo-Souza A, Reis FM. Uterine Fibroids and Pregnancy: How Do They Affect Each Other? Reprod Sci. 2022;29(8):2145-51.

Cox J, Malik M, Britten J, Lewis T, Catherino WH. Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial. Reprod Sci. 2018;25(2):198-206.

Croxtall JD. Ulipristal acetate: in uterine fibroids. Drugs. 2012;72(8):1075-85.

Forno S, Degli Esposti E, Salucci P, Leonardi D, Iodice R, Arena A, et al. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. Gynecol Endocrinol. 2020;36(5):445-7.

Deveer M, Deveer R, Engin-Ustun Y, Sarikaya E, Akbaba E, Senturk B, et al. Comparison of pregnancy outcomes in different localizations of uterine fibroids. Clin Exp Obstet Gynecol. 2012;39(4):516-8.

Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409-20.

Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409-20.

Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421-32.

Link L, Edwards TL, Jones S, Hartmann KE, Velez Edwards DR. Enhancing uterine fibroid research through utilization of biorepositories linked to electronic medical record data. J Womens Health (Larchmt). 2014;23(12):1027-32.

Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991;77(5):720-5.

Frijlingh M, De Milliano I, Hehenkamp WJK, Huirne JAF. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study. Eur J Obstet Gynecol Reprod Biol. 2020;245:186-92.

Frijlingh M, De Milliano I, Hehenkamp WJK, Huirne JAF. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study. Eur J Obstet Gynecol Reprod Biol. 2020;245:186-92.

Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. Int J Womens Health. 2017;9:403-411.

Ghonim M, Magdy R, Sabbour M, Ghonim M, Nabhan A. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids. Int J Gynaecol Obstet. 2019;146(2):141-8.

Grzechocinska B, Gadomska H, Zygula A, Wielgos M. Application of ulipristal acetate in female patients with uterine fibroids. Neuro Endocrinol Lett. 2014;35(3):175-8.

Havryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic Fibroid Management: Systematic Review of the Literature. JSLS. 2017;21(3):e2017.00041.

Heald B, Mokhtary S, Nielsen SM, Rojahn S, Yang S, Michalski ST, et al. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer. Gynecol Oncol. 2022;166(2):344-50.

Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynyen K, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol. 2004;183(6):1713-9.

Hossain MZ, Rahman MM, Ullah MM, Mukthadira M, Akter FA, Jahan AB, et al. A Comparative Study of Magnetic Resonance Imaging and Transabdominal Ultrasonography for the Diagnosis and Evaluation of Uterine Fibroids. Mymensingh Med J. 2017;26(4):821-7.

Huo T, Li L, Chen X, Wang Z, Zhang X, Liu S, Het al. Artificial intelligence-aided method to detect uterine fibroids in ultrasound images: a retrospective study. Sci Rep. 2023;13(1):3714.

Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018;24(1):59-85.

Islam MS, Protic O, Stortoni P, Grechi G, Lamanna P, Petraglia F, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013;100(1):178-93.

Iversen H, Lenz S, Dueholm M. Ultrasound-guided radiofrequency ablation of symptomatic uterine fibroids: short-term evaluation of effect of treatment on quality of life and symptom severity. Ultrasound Obstet Gynecol. 2012;40(4):445-51.

Jasonni VM, D'Anna R, Mancuso A, Caruso C, Corrado F, Leonardi I. Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. Acta Obstet Gynecol Scand. 2001;80(10):956-8.

Jasonni VM, D'Anna R, Mancuso A, Caruso C, Corrado F, Leonardi I. Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. Acta Obstet Gynecol Scand. 2001;80(10):956-8.

Baptiste H, Tetrokalashvili M, Williams T, Fogel J, Hsu CD. Characteristics associated with postoperative diagnosis of adenomyosis or combined adenomyosis with fibroids. Int J Gynaecol Obstet. 2013;122(2):112-4.

Kalampokas T, Kamath M, Boutas I, Kalampokas E. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32(2):91-6.

Kalampokas T, Kamath M, Boutas I, Kalampokas E. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32(2):91-6.

King LA, Wentzensen N, Purdue MP, Katki HA, Pinto LA, Trabert B. Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Ann Epidemiol. 2022;68:1-8.

Lippman SA, Warner M, Samuels S, Olive D, Vercellini P, Eskenazi B. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril. 2003;80(6):1488-94.

Lukes AS, Soper D, Harrington A, Sniukiene V, Mo Y, Gillard P, et al. Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2019;133(5):869-78.

Lukes AS, Soper D, Harrington A, Sniukiene V, Mo Y, Gillard P, et al. Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2019;133(5):869-78.

Maghraby N, El Noweihi AM, El-Melegy NT, Mostafa NAM, Abbas AM, El-Deek HEM, et al. Increased Expression of Fibroblast Activation Protein is Associated with Autophagy Dysregulation and Oxidative Stress in Obese Women with Uterine Fibroids. Reprod Sci. 2022;29(2):448-59.

Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt). 2018;27(11):1359-67.

Mohan A, Kumar V, Brahmachari S, Pandya B. A Study on Clinico-Pathological Profile of Breast Cancer Patients and Their Correlation With Uterine Fibroids Using Hormone Level and Receptor Status Assessment. Breast Cancer (Auckl). 2022;16:11782234221090197.

Moshesh M, Peddada SD, Cooper T, Baird D. Intraobserver variability in fibroid size measurements: estimated effects on assessing fibroid growth. J Ultrasound Med. 2014;33(7):1217-24.

Nakhaei M, Faintuch S, Brook OR. Impact of evaluation in interventional radiology clinic prior to uterine artery embolization: changes in management. Abdom Radiol (NY). 2020;45(3):878-84.

Netter A, Pauly V, Siles P, Pivano A, Vidal V, Agostini A. Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study. Reprod Biomed Online. 2019;39(5):795-801.

Osuga Y, Nakano Y, Yamauchi Y, Takanashi M. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. Fertil Steril. 2021;116(1):189-97.

Osuga Y, Nakano Y, Yamauchi Y, Takanashi M. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. Fertil Steril. 2021;116(1):189-97.

Parazzini F, Chiaffarino F, Polverino G, Chiantera V, Surace M, La Vecchia C. Uterine fibroids risk and history of selected medical conditions linked with female hormones. Eur J Epidemiol. 2004;19(3):249-53.

Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol. 1988;72(6):853-7.

Patel HH, Banerjee D, Goldrath K, Chang J, Tandel MD, Kwan L, et al. Intraoperative Laparoscopic Ultrasound Increases Fibroid Detection During Laparoscopic Myomectomy. JSLS. 2022;26(3):e2022.00038.

Sato F, Mori M, Nishi M, Kudo R, Miyake H. Familial aggregation of uterine myomas in Japanese women. J Epidemiol. 2002;12(3):249-53.

Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-2.

Szydłowska I, Grabowska M, Nawrocka-Rutkowska J, Kram A, Piasecka M, Starczewski A. Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids. J Clin Med. 2021;10(16):3721.

Tal R, Segars JH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update. 2014;20(2):194-216.

Tan N, McClure TD, Tarnay C, Johnson MT, Lu DS, Raman SS. Women seeking second opinion for symptomatic uterine leiomyoma: role of comprehensive fibroid center. J Ther Ultrasound. 2014;2:3.

Tan N, McClure TD, Tarnay C, Johnson MT, Lu DS, Raman SS. Women seeking second opinion for symptomatic uterine leiomyoma: role of comprehensive fibroid center. J Ther Ultrasound. 2014;2:3.

Verguts J, Godin PA, De Vree B, Donnez O, Cosyns S, Luyckx M, et al. Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial. Int J Gynaecol Obstet. 2019;147(3):339-43.

Verguts J, Godin PA, De Vree B, Donnez O, Cosyns S, Luyckx M, et al. Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial. Int J Gynaecol Obstet. 2019;147(3):339-43.

Vikhlyaeva EM, Khodzhaeva ZS, Fantschenko ND. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet. 1995;51(2):127-31.

Wang X, Qin J, Chen J, Wang L, Chen W, Tang L. The effect of high-intensity focused ultrasound treatment on immune function in patients with uterine fibroids. Int J Hyperthermia. 2013;29(3):225-33.

Williams VS, Jones G, Mauskopf J, Spalding J, DuChane J. Uterine fibroids: a review of health-related quality of life assessment. J Womens Health (Larchmt). 2006;15(7):818-29.

Wong JY, Gold EB, Johnson WO, Lee JS. Circulating Sex Hormones and Risk of Uterine Fibroids: Study of Women's Health Across the Nation (SWAN). J Clin Endocrinol Metab. 2016;101(1):123-30.

Xu W, Chen W, Chen J, Hu L, Su X, Nie Y, et al. Adaptability and clinical applicability of UFS-QoL in Chinese women with uterine fibroid. BMC Womens Health. 2022;22(1):372.

Xu W, Chen W, Chen J, Hu L, Su X, Nie Y, et al. Adaptability and clinical applicability of UFS-QoL in Chinese women with uterine fibroid. BMC Womens Health. 2022;22(1):372.

Yüce G, Tayarer A, Keskin HL, Genc B, Canyigit M. Ultrasound guided percutaneous radiofrequency thermal ablation of symptomatic uterine fibroids - results from a single center and 52 weeks of follow up. Ginekol Pol. 2020;91(8):447-52.

Yun BS, Seong SJ, Jung YW, Kim ML, Bae HS, Kim MK, et al. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate. Eur J Obstet Gynecol Reprod Biol. 2018;224:133-6.

Zullo F, Pellicano M, De Stefano R, Zupi E, Mastrantonio P. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors. Am J Obstet Gynecol. 1998;178(1):108-12.

Downloads

Published

2023-07-28

Issue

Section

Review Articles